Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Aquestive Therapeutics, Inc. (AQST) had Revenue of $57.56M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$57.56M
Net Income	$-44.14M
Cost of Goods Sold	$17.87M
Gross Profit	$39.69M
Operating Expenses	$88.33M
Operating Income	$-30.77M
Non-Operating Income/Expense	$-13.38M
Pre-Tax Income	$-44.15M
Normalized Pre-Tax Income	$-44.15M
Income after Taxes	$-44.14M
Income from Continuous Operations	$-44.14M
Consolidated Net Income/Loss	$-44.14M
Normalized Income after Taxes	$-44.14M
EBIT	$-30.77M
EBITDA	$-19.34M
Weighted-Average Shares Outstanding (Basic)	86.73M
Weighted-Average Shares Outstanding (Diluted)	86.73M
Earnings per Share (EPS) (Basic)	$-0.51
Earnings per Share (EPS) (Diluted)	$-0.51
Balance Sheet Financials
Current Assets	$88.22M
Property, Plant, and Equipment	$3.80M
Long-Term Assets	$13.20M
Total Assets	$101.42M
Current Liabilities	$18.86M
Long-Term Debt	$32.50M
Long-Term Liabilities	$142.72M
Total Liabilities	$161.58M
Common Equity	$-60.16M
Tangible Shareholders Equity	$-60.16M
Shareholders Equity	$-60.16M
Common Shares Outstanding	91.41M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-35.76M
Cash Flow from Investing Activities	$-0.16M
Cash Flow from Financial Activities	$83.59M
Beginning Cash	$23.87M
End Cash	$71.55M
Increase/Decrease in Cash	$47.67M
Stock-Based Compensation	$7.10M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.68
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-1.18
Debt to Equity Ratio	-0.54
Gross Margin	68.95%
Operating Margin	-53.46%
EBIT Margin	-53.46%
EBITDA Margin	-33.60%
Pre-Tax Profit Margin	-76.70%
Profit Margin	-76.68%
Free Cash Flow	$-35.92M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.57
Inventory Turnover	2.96
Receiveable Turnover	7.84
Days Sales in Receivables	46.57
Return on Equity	73.37%
Return on Tangible Equity	73.37%
Return on Assets	-43.52%
Return on Investments	159.59%
Book Value Per Share	$-0.66
Free Cash Flow per Share	$-0.41
Operating Cash Flow per Share	$-0.41

Data from Zacks Investment Research, Inc.